Skip to content

D&A at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$3.3M+48.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$439K-8.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$227K-7.0%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$3.01M-2.4%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$295K+4.2%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$10.59M+6.2%

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's D&A?
CalAmp (CAMP) reported D&A of $520K in Q1 2026.
How has CalAmp's D&A changed year-over-year?
CalAmp's D&A increased by 23.5% year-over-year, from $421K to $520K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.